The global recombinant proteins market is projected to reach USD 1.7 billion by 2026 from USD 1.0 billion in 2021, at a CAGR of 9.8% during the forecast period. Market growth is largely driven by factors such as increasing government investments and R&D expenditure in pharmaceutical & biotechnology companies, growing industry-academia collaborations, and the patent expiry of biologics. The emerging Asian countries are also expected to offer strong growth opportunities for players in the recombinant proteins market.
The global recombinant proteins market is fragmented. The prominent players operating in this market include Thermo Fisher Scientific, Inc. (US), Miltenyi Biotech (Germany), Sino Biological Inc. (China), Merck KGaA (Germany), Abcam plc (UK), Biolegend (US), Bio-Rad Laboratories, Inc. (US), GenScript Biotech Corporation (China), Enzo Life Sciences, Inc. (US), BPS Bioscience, Inc. (US), PeproTech, Inc. (US), Proteintech Group, Inc. (US), Abnova Corporation (Taiwan), R&D Systems (US), STEMCELL Technologies Inc (Canada), Other players operating in the market include RayBiotech Inc (US), CellGenix GmbH (Germany), ACROBiosystems (US), ProSpec-TechnoGene Ltd. (Israel), Neuromics (US), RICHCORE LIFESCIENCES PVT LTD (India), Icosagen AS (US), ProteoGenix (France), United States Biological (US), StressMarq Biosciences Inc (Canada), and Aviva Systems Biology Corporation (US).
To know about the assumptions considered for the study download the pdf brochure
R&D Systems (US) is a subsidiary of Bio-Techne Corporation. R&D Systems is one of the leading player in the recombinant proteins market and offers a wide range of products. The company does not depend on a key source of suppliers for the manufacturing of recombinant proteins. The end users of the company include academia, government, pharmaceutical & biotech companies, companion diagnostic, and therapeutic customers, especially customers engaged in the development of cell and gene-based therapies.
Thermo Fisher Scientific Inc. (US) is a prominent player in the recombinant proteins market, owing to its wide product range, strong sales & distribution network, and significant global footprint. The company offers a wide variety of recombinant proteins for various applications, including cell growth and differentiation, cell signaling, and studies involving disease onset and progression. The company caters to more than 400,000 customers in the pharmaceutical & biotechnology industry; hospitals, clinical diagnostics, and research laboratories; and universities and government agencies. The company adopted a combination of organic and inorganic growth strategies to maintain its leading position in the life sciences business. The company has developed a global footprint and aims to expand its customer base in the emerging and high-growth regions. The company’s focus on the APAC market is evident through the increasing share of this region in Thermo Fisher’s revenue
Merck KGaA (Germany) is a leading science and technology company having a strong global presence in more than 120 countries. The company has a portfolio of more than 300,000 life science products that support a broad customer base. Merck majorly focuses on expansions in key geographies to increase its customer base. The company specifically focuses on the high-growth Asia Pacific region to increase its market share and revenue. In the last three years, the company opened life science centers in China, India, South Korea, and Singapore to facilitate the supply of its products in the region.
Recombinant Proteins Market by Product (Growth Factors, Chemokines, Structural Proteins, Membrane Proteins), Application (Drug Discovery & Development, Academic Research), End User (Biotechnology Companies, CROs) - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE